Biotech Breakthroughs and Emerging Market Strength Lead Pre-Market Gains

📈 Today's Key Themes

The pre-market landscape is dominated by significant breakthroughs in the biotech sector, coupled with strong performance in emerging markets. Scancell Holdings (#SCLP) has reported groundbreaking Phase 2 data for its cancer treatment, while RTW Biotech Opportunities (#RTW) celebrates the successful IPO of Evommune. These developments are likely to bolster investor confidence in the biotech industry. Meanwhile, emerging markets continue to show resilience, as evidenced by JPMorgan Global Emerging Markets Income Trust (#JEMI)'s strong annual results. However, the airline sector faces challenges, with Wizz Air (#WIZZ) adjusting its capacity plans. The overall sentiment leans positive, but with notable exceptions in the financial services sector.

💡 Company Updates

JPMorgan Global Emerging Markets Income Trust (#JEMI) has reported impressive annual results, with a NAV total return of +14.1%, outperforming its benchmark. The trust increased its total dividend by 3.7% to 5.6p per share, demonstrating its ability to generate income in challenging markets. With a positive outlook for emerging markets, JEMI appears well-positioned for future growth. ME Group International (#MEGP) anticipates another year of record profitability, with total revenue expected between £311 million and £318 million, and profit before tax between £76 million and £79 million. The company's laundry operations delivered double-digit revenue growth, installing a record 1,145 net laundry machines during the year. This strong performance underscores ME Group's successful business model and growth strategy. In contrast, Record plc (#REC) reported lower H1 profits and revenue as it transitions to higher margin business. Operating profit decreased by 20% to £4.5 million, while total revenue fell 9% to £19.2 million. Despite maintaining the interim dividend at 2.15 pence per share, the financial metrics show significant declines, indicating challenges in the company's transition period.

🎯 Leading Developments

Scancell Holdings (#SCLP) has presented highly positive Phase 2 data for its lead Immunobody® product iSCIB1+ in late-stage melanoma. The treatment showed 78% 11-month progression-free survival, compared to 46% historic 12-month PFS with doublet checkpoint therapy. This breakthrough positions iSCIB1+ as a potential new benchmark for melanoma treatment, with Scancell now accelerating development plans, including regulatory and partnering discussions. Read more The biotech sector received another boost as RTW Biotech Opportunities (#RTW) announced the successful IPO of Evommune, raising $150 million on the New York Stock Exchange. The IPO price represented a 22% step-up to the holding value and a 102% step-up from cost. Evommune's stock traded up 26% on the first day, signaling strong investor confidence in the company's potential. This successful exit validates RTW's investment strategy and bolsters the fund's performance. Read more Wizz Air Holdings (#WIZZ) has reached an agreement with Airbus to reschedule its current order book, deferring 88 deliveries from fiscal year 2030 to fiscal year 2033. The airline has also reduced its commitment for A321XLRs from 47 to 11, converting 36 to A321neos. This strategic move aligns with Wizz Air's target of 10-12% seat capacity growth rate through 2030 and reinforces its position as one of the world's most emissions-efficient airlines. While this adjustment may impact short-term growth, it demonstrates a focus on sustainable, profitable expansion in the long run. Read more

📅 Week Ahead

10 November 2025: Dalata Hotel Group plc (#DAL) Cancellation of Dalata shares from trading
10 November 2025: Catenai PLC (#CTAI) Alludium to launch AI Agent collaboration platform at Web Summit in Lisbon
10 November 2025: Mosman Oil and Gas Limited (#MSMN) Annual General Meeting - Proposed change of company name to Quantum Helium Limited
11 November 2025: Princes Group plc (#PRN) Q3 trading update release
11 November 2025: Dialight plc (#DIA) Interim Results Announcement
11 November 2025: Headlam Group plc (#HEAD) Further details of the restructuring programme to be presented
12 November 2025: Experian plc (#EXPN) Release of half-year results
12 November 2025: Persimmon Plc (#PSN) Full Year 2025 Results
12 November 2025: Fidelity Emerging Markets Limited (#FEML) Trade Date for Repurchase
13 November 2025: Intermediate Capital Group plc (#ICG) Half year results announcement
13 November 2025: ConvaTec Group PLC (#CTEC) Trading update for the 10 months ending 31 October 2025
13 November 2025: Burberry Group plc (#BRBY) Burberry to issue Interim Results for the 26 weeks ending 27 September 2025
13 November 2025: Persimmon Plc (#PSN) Next scheduled update
14 November 2025: Imperial Brands PLC (#IMB) Full Year Results for 2025
14 November 2025: United Utilities Group PLC (#UU.) Announcement of half year results for the six months ending 30 September 2025
14 November 2025: Renishaw plc (#RSW) Half-Year Results
14 November 2025: Maven Renovar VCT Ord (#MRV) Payment of interim and special dividend totaling 5.00p per Ordinary Share

View full calendar

Market Summary